INHIBIN A

INHIBIN A is a specialized diagnostic endocrine and oncological test designed to measure the concentration of Inhibin A in the blood. Inhibin A is a dimeric glycoprotein hormone produced primarily by the ovary (specifically the corpus luteum and placenta) and by certain gonadal tumors. Measuring serum Inhibin A levels is essential for second-trimester prenatal screening (as part of the quad screen for Down syndrome), evaluating ovarian function, and monitoring ovarian granulosa cell tumors.

Measurement of serum Inhibin A provides direct clinical insight into fetoplacental health during pregnancy and gonadal tumor activity in gynecological oncology. Because timely identification of chromosomal anomalies or tumor recurrence supports appropriate clinical management, specialized biochemical testing supplies essential clinical data for obstetrics, gynecology, maternal-fetal medicine, and oncology evaluations.

The test requires a blood specimen collected by a qualified person using standard serum containers under appropriate clinical conditions, followed by precise analysis using automated laboratory immunoassay techniques. Results must always be interpreted in conjunction with the patient's gestational age, maternal weight, ultrasound findings, or oncological history.

Benefits of INHIBIN A Testing

• Provides a precise quantitative measurement of serum Inhibin A hormone levels.
• Helps assess second-trimester prenatal risk for Down syndrome as part of the quad screen.
• Assists obstetricians and maternal-fetal medicine specialists in evaluating fetoplacental status.
• Aids in diagnosing and monitoring ovarian granulosa cell tumors and mucinous epithelial tumors.
• Supports tracking of specialized oncological and reproductive care plans.
• Complements AFP, hCG, estriol (uE3), and ultrasound examinations.
• Utilizes precise laboratory immunoassay techniques for reliable quantitative results.
• Assists specialists in determining appropriate obstetric or oncological management strategies.
• Provides dependable turnaround times to support specialized clinical care.
• Utilizes standard venous blood collection procedures under medical supervision.

Clinical Indications and Applications

Prenatal Screening: The primary clinical indication during pregnancy is second-trimester maternal serum screening (quad screen) to evaluate the risk of fetal chromosomal abnormalities, particularly Trisomy 21 (Down syndrome).

Oncological Assessment: The test is utilized when monitoring patients diagnosed with ovarian granulosa cell tumors or assessing recurrence risk in gynecological oncology.

Why Doctors Recommend This Test

Obstetricians, gynecologists, oncologists, and maternal-fetal medicine specialists recommend this test when performing prenatal chromosomal risk assessments or monitoring specific gynecological tumors. It delivers essential quantitative data required to guide safe clinical intervention.

Following proper blood collection guidelines will ensure a smooth and efficient testing procedure.

What Happens During The Procedure?

The collection procedure involves obtaining a blood specimen drawn from a vein by a qualified phlebotomist using a clean, standard collection container provided by the healthcare facility under appropriate supervision protocols.

Once obtained, the sample is tested in the laboratory using advanced immunoassay analyzers to quantify Inhibin A concentrations. The procedure takes only a few minutes.

Normal Reporting Time

The report for the INHIBIN A test is generally available within 24 to 48 hours due to standard laboratory processing times. Results must be reviewed promptly with the referring obstetrician, gynecologist, or specialist.

Who Should Consider This Test?

• Pregnant women undergoing second-trimester quadruple screening for chromosomal abnormalities.
• Patients evaluated or monitored for ovarian granulosa cell tumors as directed by a clinician.

Understanding Test Results

Test results provide quantitative concentrations of serum Inhibin A, evaluated against established gestational age-matched reference ranges or tumor marker cutoffs.

Normal Findings: Normal Inhibin A levels indicate typical fetoplacental development during pregnancy or absence of gonadal tumor activity in non-pregnant individuals.

Abnormal Findings: Elevated Inhibin A levels during pregnancy may indicate increased risk for Down syndrome, while elevated levels in non-pregnant individuals can suggest the presence or recurrence of an ovarian granulosa cell tumor, requiring specialist review.

Clinical Limitations

Inhibin A levels vary significantly depending on gestational week during pregnancy; accurate dating and clinical correlation are essential for proper interpretation.

Important Safety Information

Severe pregnancy complications, acute pelvic pain, or abnormal bleeding require immediate medical attention. Patients must consult their healthcare provider or specialist to interpret Inhibin A findings.